Neoplasms, Plasma Cell: all 2,314 studies
Page 19 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.
- Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma PatientsCompletedNCT00950768Phase 3
- Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic SyndromeTerminatedNCT00946283Not applicable
- Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT00938626Phase 1
- Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple MyelomaCompletedNCT00937183Not applicable
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT00935090
- Busulfan in Multiple MyelomaTerminatedNCT00934232Phase 1
- Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple MyelomaCompletedNCT00934154Phase 3
- Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple MyelomaStatus unknownNCT00932217Phase 3
- Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple MyelomaCompletedNCT00925821Phase 2
- S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.CompletedNCT00919139
- Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic CancerTerminatedNCT00918658
- A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple MyelomaCompletedNCT00915408Phase 1/2
- A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00912899Phase 1
- Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and DexamethasoneCompletedNCT00911105
- Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)Status unknownNCT00910897Phase 3
- Serum Free Light Change in Multiple MyelomaCompletedNCT00910078
- Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasoneCompletedNCT00907452Not applicable
- Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal FailureStatus unknownNCT00902915Phase 2
- Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell TransplantCompletedNCT00900406
- S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or PlasmacytomaCompletedNCT00900263
- Collecting and Storing Blood Samples From Patients With CancerWithdrawnNCT00900120
- Blood Samples From Patients on a Clinical Trial to CINV During HSCTTerminatedNCT00900068
- Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or MyelomaCompletedNCT00900055
- Studying Fentanyl in Patients With CancerTerminatedNCT00899951
- Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or LenalidomideCompletedNCT00899080
- S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood DiseaseCompletedNCT00898066
- Study of DNA Samples From Patients With Multiple MyelomaCompletedNCT00898040
- Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for MyelomaSuspendedNCT00892346Phase 3
- Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple MyelomaCompletedNCT00891384Phase 3
- Dose-escalation Study of Oral CX-4945Status unknownNCT00891280Phase 1
- Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic MalignancyCompletedNCT00891137Phase 1
- Panobinostat/Velcade in Multiple MyelomaTerminatedNCT00891033Phase 1
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- Tumor Registry of Lymphatic NeoplasiaCompletedNCT00889798
- Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple MyelomaCompletedNCT00882063Phase 1/2
- Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALLActive, not recruitingNCT00881920Phase 1
- S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone MetastasesCompletedNCT00874211
- Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) PatientsStatus unknownNCT00872352Phase 3
- PHA-739358 for the Treatment of Multiple MyelomaTerminatedNCT00872300Phase 2
- Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior TherapyActive, not recruitingNCT00871013Phase 2
- Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3CompletedNCT00866138Phase 2
- A Bioequivalence Study of SPARC_147709 in Patients With Multiple MyelomaCompletedNCT00863174Phase 1
- A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid MalignanciesCompletedNCT00861510Phase 1
- Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma PatientsTerminatedNCT00857324Phase 1/2
- Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)CompletedNCT00854139Phase 1
- Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple MyelomaCompletedNCT00847639Phase 2
- A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).CompletedNCT00838357Phase 3
- Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced MyelomaCompletedNCT00834665Phase 1
- Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced CancerCompletedNCT00823524Phase 1/2
- Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple MyelomaStatus unknownNCT00821301Phase 1
- A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00821249Phase 1/2
- PAD. ICORG 05-01, V11CompletedNCT00814541Phase 2
- Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other DiseasesTerminatedNCT00813501
- Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological CancerCompletedNCT00806767Phase 2
- Study of ENMD-2076 in Patients With Multiple MyelomaCompletedNCT00806065Phase 1
- Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to TreatmentCompletedNCT00802568Phase 2
- Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to TreatmentTerminatedNCT00800150Phase 1
- A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma PatientsNo longer availableNCT00799539
- Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
- Stem Cell Mobilization With Pegfilgrastim in Lymphoma and MyelomaCompletedNCT00794261Phase 2
- Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00792506Phase 2
- Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal FunctionCompletedNCT00779922Phase 2
- Dose-finding of Lenalidomide as Maintenance in Multiple MyelomaCompletedNCT00778752Phase 1/2
- Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple MyelomaCompletedNCT00777998Phase 2
- Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple MyelomaTerminatedNCT00775502Phase 1
- Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple MyelomaCompletedNCT00772811Phase 2
- Perceptions of Burden in Patients With Late-Stage Cancer and Their CaregiversWithdrawnNCT00770419
- Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple MyelomaCompletedNCT00761722Phase 1
- Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast CancerCompletedNCT00760370Phase 2
- A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma PatientsCompletedNCT00752518Phase 1/2
- Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical TrialCompletedNCT00750009Phase 3
- Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.TerminatedNCT00748631Not applicable
- High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After ChemotherapyStatus unknownNCT00747877Phase 3
- Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00744354Phase 1
- Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT00742404Phase 2
- Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).CompletedNCT00741780
- A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma PatientsCompletedNCT00741377Phase 1
- Stem Cell Transplant in Treating Patients With Hematological Cancer or Other DisordersStatus unknownNCT00740467Phase 2
- Stage I Multiple Myeloma TreatmentCompletedNCT00733538Phase 4
- RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple MyelomaCompletedNCT00729638Phase 1
- Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT00729118Phase 1
- A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.TerminatedNCT00726869Phase 1
- A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple MyelomaCompletedNCT00725634Phase 1
- Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantTerminatedNCT00725062Phase 1
- Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00723359Phase 1
- Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple MyelomaCompletedNCT00722488Phase 1
- This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.No longer availableNCT00720603
- Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed MyelomaCompletedNCT00718601Phase 1
- Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell TransplantCompletedNCT00716911Not applicable
- Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic MalignanciesCompletedNCT00710528Phase 1
- A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.CompletedNCT00708292Phase 1/2
- A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With BortezomibWithdrawnNCT00706953Phase 2
- Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)Status unknownNCT00702247Phase 2
- Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in MyelomaCompletedNCT00698776Phase 1
- Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple MyelomaCompletedNCT00693433Phase 1
- A Phase 1 Safety Study of LY2127399 in Combination With BortezomibCompletedNCT00689507Phase 1
- Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)CompletedNCT00689000Phase 1/2
- Inflammatory Cytokines in Symptom Production in Multiple MyelomaCompletedNCT00688168
- Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).CompletedNCT00665314Phase 2
- A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00664898Phase 1